Stock Scorecard
Stock Summary for CytomX Therapeutics Inc (CTMX) - $3.32 as of 10/29/2025 3:06:18 PM EST
Total Score
17 out of 30
Safety Score
35 out of 100
Currently on the following lists
None
Tim's Recommendation
Possible Buy
Growth List Algorithm Criteria for CTMX
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for CTMX
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for CTMX
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for CTMX
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for CTMX (35 out of 100)
| Stock Price Rating (Max of 10) | 3 |
| Historical Stock Price Rating (Max of 10) | 3 |
| Stock Price Trend (Max of 10) | 2 |
| Book Value (Max of 10) | 1 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 4 |
| Analyst Strong Buy Ratings (Max of 5) | 4 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 9 |
| Price to Earnings (Max of 10) | 9 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for CTMX
Financial Details for CTMX
Company Overview |
|
|---|---|
| Ticker | CTMX |
| Company Name | CytomX Therapeutics Inc |
| Country | USA |
| Description | CytomX Therapeutics, Inc., based in South San Francisco, California, is a pioneering biopharmaceutical company focused on revolutionizing cancer treatment through its proprietary Probody™ technology platform. This innovative approach aims to create highly selective therapeutics that reduce off-tumor effects while enhancing targeted anti-tumor activity, addressing critical unmet needs in oncology. With a promising pipeline of product candidates at various clinical stages, CytomX is well-positioned to improve patient outcomes and transform cancer treatment paradigms. The company's strategic emphasis on partnerships and collaborations further enhances its potential to make a significant impact within the biopharmaceutical sector. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 6/30/2025 |
| Next Earnings Date | 11/6/2025 |
Stock Price History |
|
| Last Day Price | 3.32 |
| Price 4 Years Ago | 4.33 |
| Last Day Price Updated | 10/29/2025 3:06:18 PM EST |
| Last Day Volume | 1,458,773 |
| Average Daily Volume | 4,016,610 |
| 52-Week High | 3.91 |
| 52-Week Low | 0.40 |
| Last Price to 52 Week Low | 730.00% |
Valuation Measures |
|
| Trailing PE | 6.64 |
| Industry PE | 23.04 |
| Sector PE | 40.93 |
| 5-Year Average PE | -13.47 |
| Free Cash Flow Ratio | 11.07 |
| Industry Free Cash Flow Ratio | 14.83 |
| Sector Free Cash Flow Ratio | 29.03 |
| Current Ratio Most Recent Quarter | 4.20 |
| Total Cash Per Share | 0.30 |
| Book Value Per Share Most Recent Quarter | 0.73 |
| Price to Book Ratio | 4.51 |
| Industry Price to Book Ratio | 29.98 |
| Sector Price to Book Ratio | 32.16 |
| Price to Sales Ratio Twelve Trailing Months | 3.88 |
| Industry Price to Sales Ratio Twelve Trailing Months | 33.56 |
| Sector Price to Sales Ratio Twelve Trailing Months | 16.96 |
| Analyst Buy Ratings | 4 |
| Analyst Strong Buy Ratings | 3 |
Share Statistics |
|
| Total Shares Outstanding | 164,913,000 |
| Market Capitalization | 547,511,160 |
| Institutional Ownership | 90.21% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 60.60% |
| Annual Earnings Growth | 5,700.88% |
| Reported EPS 12 Trailing Months | 0.50 |
| Reported EPS Past Year | 0.27 |
| Reported EPS Prior Year | 0.39 |
| Net Income Twelve Trailing Months | 47,983,000 |
| Net Income Past Year | 31,869,000 |
| Net Income Prior Year | -569,000 |
| Quarterly Revenue Growth YOY | -25.70% |
| 5-Year Revenue Growth | 19.16% |
| Operating Margin Twelve Trailing Months | -6.89% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 49,041,000 |
| Total Cash Past Year | 38,052,000 |
| Total Cash Prior Year | 17,171,000 |
| Net Cash Position Most Recent Quarter | 49,041,000 |
| Net Cash Position Past Year | 38,052,000 |
| Long Term Debt Past Year | 0 |
| Long Term Debt Prior Year | 0 |
| Total Debt Most Recent Quarter | 0 |
| Equity to Debt Ratio Past Year | 0.00 |
| Equity to Debt Ratio Most Recent Quarter | 1.00 |
| Total Stockholder Equity Past Year | -456,000 |
| Total Stockholder Equity Prior Year | -47,447,000 |
| Total Stockholder Equity Most Recent Quarter | 119,910,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -77,678,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -0.47 |
| Free Cash Flow Past Year | -86,541,000 |
| Free Cash Flow Prior Year | -56,875,000 |
Options |
|
| Put/Call Ratio | 1.48 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.23 |
| MACD Signal | 0.27 |
| 20-Day Bollinger Lower Band | 1.56 |
| 20-Day Bollinger Middle Band | 2.53 |
| 20-Day Bollinger Upper Band | 3.51 |
| Beta | 2.27 |
| RSI | 54.66 |
| 50-Day SMA | 1.66 |
| 150-Day SMA | 1.66 |
| 200-Day SMA | 1.81 |
System |
|
| Modified | 10/29/2025 9:10:08 PM EST |